Company: SHPH
Filing Date: 2025-02-13
Form Type: S-1
Source: 0001493152-25-006202
Chunk: 164

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-13
Form: S-1
Chunk 164
---
 document filed as an exhibit to the registration statement. The SEC maintains an Internet website at http://www.sec.gov that contains reports, proxy and information statements, and other information regarding registrants that file electronically with the SEC.

We file periodic reports and current reports under the Exchange Act, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and other information with the SEC. These periodic reports and other information are available for inspection and copying at the SEC regional offices, public reference facilities and on the website of the SEC referred to above.

We make available free of charge on or through our internet website our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. The information found on our website, https://shuttlepharma.com, other than as specifically included in this prospectus, is not part of this prospectus.

| 98 |

<div align='center'>SHUTTLE PHARMACEUTICALS HOLDINGS, INC.

Consolidated Financial Statements

Contents</div>

| Condensed                                                                                                                   
 Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023 (unaudited)                                      
 Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2024 and 2023 (unaudited) | Page 
 F-2  
 F-3  |
|:----------------------------------------------------------------------------------------------------------------------------|:-----|
| Condensed                                                                                                                   
 Consolidated Statements of Changes in Stockholders’ Equity (Deficit) for the three and nine months ended September 30,      
 2024 and 2023 (unaudited)                                                                                                   | F-4  |
| Condensed                                                                                                                   
 Consolidated Statements of Cash Flows for the three and nine months ended September 30, 2024 and 2023 (unaudited)           | F-5  |
| Notes                                                                                                                       
 to Condensed Consolidated Financial Statements (unaudited)                                                                  | F-6  |

| Report                                                                                       
 of Independent Registered Public Accounting Firm, Forvis Mazars LLP (PCAOB ID 686)           
 Consolidated                                                                                 
 Balance Sheets as of December 31 202